Crossmark

An Antimicrobial susceptibility study to compare the in vitro activity of antimicrobial agents in the Philippines against Enterobacterales and Pseudomonas aeruginosa from different infection sites: results from ATLAS surveillance program (2018–2021)

Crossref DOI link: https://doi.org/10.1186/s12879-026-13396-2

Published Online: 2026-05-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Mendoza, Myrna

Lagamayo, Evelina

Barez, Marie Yvette

Wadhwa, Vaidehi

Payawal, Evan
Funding

Funding for this research was provided by:

Pfizer Limited
License Information

Text and Data Mining valid from 2026-05-10

Version of Record valid from 2026-07-06
More Information

Article History

Received: 30 September 2025

Accepted: 17 April 2026

First Online: 10 May 2026

Declarations

:

: Institutional Review Board (IRB) assessment was requested from the St Luke’s Medical Center Institutional Ethics Review Committee (IERC), Davao Doctor’s Hospital Research Ethics Committee (REC), and National Kidney and Transplant Institute Research Ethics Committee (REC). The collection of isolates and anonymized demographic patient data was done according to all relevant guidelines and regulations. Individual patient consent was assessed by IRB in each institution to be not needed.

: Not Applicable.

: MM declares no conflict of interest. EL has received honoraria from Pfizer for consultancy as speaker and advisory board member. MYB has received honoraria from Pfizer for consultancy as speaker and advisory board member. VW is a full-time employee of Pfizer Products India Private Limited and owns Pfizer stock. EP is a full-time employee of Pfizer Philippines Inc.

Document is current

Any future updates will be listed below